Latest news with #Foralumab
Yahoo
30-04-2025
- Business
- Yahoo
Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025
We recently published a list of . In this article, we are going to take a look at where Tiziana Life Sciences Ltd (NASDAQ:TLSA) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it's a good idea to have exposure to it. Most executives now hold a favorable view of the industry's prospects, a notable increase from 52% just a year ago. Moreover, it's an industry that is more insulated from tariffs and macro risks. Of course, the top gainers here are not defensive healthcare stocks, but it's still worth looking into the winners here if you are chasing potential multibaggers. Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified in another article. For this article, I screened the best-performing healthcare stocks year-to-date. I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A biotechnology expert discussing the potential of a new anti-CD73 monoclonal antibody in a lecture hall. Number of Hedge Fund Holders In Q4 2024: N/A Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotechnology company developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases, with a lead focus on its fully human anti-CD3 monoclonal antibody, Foralumab, for conditions such as secondary progressive multiple sclerosis, Alzheimer's disease, and ALS. The stock has surged in 2025, primarily due to significant progress in clinical development and strategic updates. The most notable catalyst was the announcement that Tiziana Life Sciences Ltd (NASDAQ:TLSA) would begin a Phase 2 clinical trial of intranasal Foralumab for mild Alzheimer's disease in the first half of 2025, following successful IND submissions and expanded access programs for both Alzheimer's and non-active secondary progressive multiple sclerosis. In December 2024, the company began dosing patients with moderate Alzheimer's under an expanded access program, which further fueled investor optimism. Additionally, Tiziana received a grant from the ALS Association to support a Phase 2 clinical trial in ALS. Tiziana Life Sciences Ltd (NASDAQ:TLSA) stock is up 95.35% year-to-date. Overall, TLSA ranks 12th on our list of healthcare stocks that are surging in 2025. While we acknowledge the potential of TLSA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TLSA but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Boston Globe
12-02-2025
- Health
- Boston Globe
Quincy man becomes first Alzheimer's patient to try nasal spray drug: ‘I'm hoping like heck'
Walsh, of Quincy, started having trouble recalling words and having conversations about five years ago. He'd mix up words and sometimes wouldn't make sense. The condition, called aphasia, is tied to his moderate Alzheimer's, which he was diagnosed with in 2019. People associate Alzheimer's with dementia, but aphasia is 'more common than gets appreciated,' said Seth Gale, Walsh's neurologist. For the past nine weeks, Walsh has been receiving the nasal spray treatment, called Foralumab, after the FDA approved it for just one Alzheimer's patient in the US. It's giving his wife and two children hope. Advertisement Joe Walsh walks his dog near his home in Quincy, Mass. Walsh and his family maintain normal routines while he participates in a unique Alzheimer's treatment. Erin Clark/Globe Staff 'I know there's a break right around the corner, and I'm hoping like heck it's this drug,' Karen Walsh, 65, said Tuesday. Doctors at Brigham and Women's Hospital applied to the FDA for Walsh's approval, and the agency chose him without knowing his identity. There's already evidence the spray could help stop the advance of some forms of multiple sclerosis, said Gale, an investigator at the Center for Alzheimer's Research and Treatment at Brigham and Women's. In Walsh's case, doctors will see whether the drug diminishes the activity of cells causing inflammation in the brain, a key factor in the disease's progression, Gale said. Researchers will analyze Walsh's brain activity in March to see if the drug is having an impact by 'tamping down' further spread of his Alzheimer's, Gale said. They will also test to see if an Alzheimer's patient can 'tolerate' the use of the nasal spray over a 6-month regimen. For now, he added, 'the jury's out.' Walsh's speech may not improve as part of treatment. Two Alzheimer's drugs released in the past 18 months aren't available to Walsh, as someone with moderately advanced progression, Gale said. Those drugs, Lecanemab and Donanemab, made headlines because they have a 'disease-modifying effect,' but they're only available to people with mild Alzheimer's. Joe Walsh, 79, sits in the window seat of his Quincy, Mass., home surrounded by family photos. Erin Clark/Globe Staff Brigham and Women's hopes to launch an official clinical trial for Foralumab 'maybe later in 2025,' Gale said, and it would be for patients with mild Alzheimer's, allowing for more effective analyses of symptoms, Gale said. Advertisement 'It's like studying heart disease before a heart attack happens,' he said. Walsh's wife said the spray, which Joe takes three times per week, makes the family feel as if they have agency against a ruthless disease that affects millions of Americans. Walsh is the first to take the spray, but preliminary results will inform future treatment, his wife said. 'I feel like at least we're taking action, we're not just sitting back living day to day, we're actually doing something; whether Joe sees results, we're helping others,' Karen Walsh said. The couple's extended family, who don't see Joe daily, have told his wife they've noticed changes in his behavior over the past nearly three months. 'They think he's kind of more in tune and aware of things than he had been,' she said. That came through most clearly during a group outing to the theaters to see 'Wicked.' Joe was not a fan of the 2.5-hour-long musical movie adaptation, his wife said. 'He looked over at me and said, 'Let's go,'' Karen said. 'Later I looked over at him and he rolled his eyes; that seemed like a positive.' In a brief phone conversation, Joe Walsh indicated he is looking forward to a Valentine's dinner with his wife at The Reel House at Quincy's Marina Bay. Last week, the family also enjoyed a trip to visit their son in New York City, where they attended an NHL game between the Bruins and the Rangers. 'We try to keep things as normal as possible,' his wife said, 'and really focus on where we are today.' Advertisement Claire Thornton can be reached at
Yahoo
11-02-2025
- Health
- Yahoo
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ('Tiziana' or the 'Company'), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its investigational drug, intranasal foralumab, was featured on a prominent News Channel. The segment highlighted the experiences of the first patient dosed in the company's expanded access program for moderate Alzheimer's disease. In the segment, Joe and his Wife, Karen, shared their journey and shed light on the hope that innovative therapies like Foralumab offer for individuals battling moderate Alzheimer's, a condition that currently has no cure and limited treatment options. Watch the full interview here: Dr. Howard Weiner, Co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system commented 'Foralumab, administered via a novel intranasal delivery method, aims to target immune system dysregulation associated with Alzheimer's disease, potentially slowing disease progression and improving cognitive function. The recent coverage in the News underscores the growing recognition of Foralumab's promise in the field of neurodegenerative diseases.' Foralumab's mechanism of action involves modulating the immune system to reduce inflammation, which has been linked to neurodegeneration in Alzheimer's. The expanded access program enables patients who do not have access to clinical trials to receive this promising treatment as part of a compassionate use initiative. Microglial activation is increasingly recognized as a critical component of neurodegenerative diseases, including Alzheimer's, secondary progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease. In Alzheimer's, this activation contributes to the pathogenesis alongside increased beta-amyloid and tau protein levels. Cognitive dysfunction in AD has been linked to both tau accumulation and microglial activation, highlighting the need for treatments beyond amyloid-targeting therapies. Nasal foralumab, a fully human anti-CD3 monoclonal antibody, has shown efficacy in dampening microglial activation through the induction of Tregs, which travel to the brain and modulate neuroinflammation. This therapeutic effect has been validated in animal models and observed in subjects with secondary progressive MS. Nasal foralumab also holds promise as a potential adjunctive therapy that addresses a major component of AD pathogenesis not targeted by anti-amyloid therapies. About Foralumab Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program with either an improvement or stability of disease seen within 6 months in all patients. The FDA has recently allowed an additional 20 patients to be enrolled in this EA program. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923). Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development, binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been observed in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2] About Tiziana Life Sciences Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications. For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit Forward-Looking Statements Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Tiziana's Annual Report on Form 20-F for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. For further inquiries: Tiziana Life Sciences LtdPaul Spencer, Business Development, and Investor Relations+44 (0) 207 495 2379email: info@ A video accompanying this announcement is available at: ____________________[1] in to access your portfolio
